The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial
Abstract
Fecal microbial transplantation (FMT) from lean donors to patients with obesity has been associated with metabolic benefits, yet results so far have been inconsistent. In this study, we tested the application of daily fiber supplementation as an adjunct to FMT therapy to modulate cardiometabolic outcomes. We performed a double-blind randomized trial in patients with severe obesity and metabolic syndrome receiving oral FMT, to test high-fermentable (HF) and low-fermentable (LF) fiber supplements (NCT03477916). Seventy participants were randomized to the FMT-HF (n = 17), FMT-LF (n = 17), HF (n = 17) and LF (n = 19) groups. The primary outcome was the assessment of change in insulin sensitivity from baseline to 6 weeks using the homeostatic model assessment (HOMA2-IR/IS). After 6 weeks, only patients in the FMT-LF group had significant improvements in HOMA2-IR (3.16 ± 3.01 at 6 weeks versus 3.77 ± 3.57 at baseline; P = 0.02). No difference in HOMA2-IR was observed over this period for those in the FMT-HF group (3.25 ± 1.70 at 6 weeks versus 3.17 ± 1.72 at baseline; P = 0.8), the HF group (3.49 ± 1.43 at 6 weeks versus 3.26 ± 1.33 at baseline; P = 0.8) or the LF group (3.76 ± 2.01 at 6 weeks versus 3.56 ± 1.81 at baseline; P = 0.8). Interventions were safe and well-tolerated with no treatment-attributed serious adverse events. We provide proof of concept for the use of a single-dose oral FMT combined with daily low-fermentable fiber supplementation to improve insulin sensitivity…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This concept is supported by evidence that the high efficacy rate of FMT in rCDI is not observed under other conditions where the characteristics of donors, 26,39 recipients, 41,42 and working protocols, 43 appear to largely impact clinical outcomes.”
From Key determinants of success in fecal microbiota transplantation: From microbiome to clinic (2023) · cites this paper as [43]
In the citing paper
“Notably, in a randomized controlled trial of patients with severe obesity and MetS, postFMTsupplementation with LF fibers (specifically microcrystalline cellulose fiber) was more effective than high-fermentable (HF) fibers in promoting microbial engraftment and improving insulin sensitivity.”
From Key determinants of success in fecal microbiota transplantation: From microbiome to clinic (2023) · cites this paper as [43]
Citations
Cites
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638
The Epidemiology of Obesity: A Big Picture
Hruby, A., & Hu, F. B. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0243-x · Cited by 3,207
The gut microbiota, bacterial metabolites and colorectal cancer
Louis, P., Hold, G. L., & Flint, H. J. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3344 · Cited by 2,925
Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
The impact of dietary fiber on gut microbiota in host health and disease
Makki, K., Deehan, E. C., Walter, J., & Bäckhed, F. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.05.012 · Cited by 2,517
Self-citationCommensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Obesity and inflammation: the linking mechanism and the complications
Ellulu, M. S., Patimah, I., Khaza’ai, H., Rahmat, A., & Abed, Y. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.58928 · Cited by 1,982
Dansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P., & Schaefer, E. J. (2005) · JAMA · doi:10.1001/jama.293.1.43 · Cited by 1,726
Obesity and Severe Obesity Forecasts Through 2030
Finkelstein, E. A., Khavjou, O., Thompson, H. F., Trogdon, J. G., Pan, L., Sherry, B., & Dietz, W. H. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.10.026 · Cited by 1,418
Research works printed but not linked: 1
- Chis, R., Sheth, P. M. & Petrof, E. O. in Mechanisms Underlying Host–Microbiome Interactions in Pathophysiology of Human Diseases. Physiology in Health and Disease (eds Sun, J. & Dudeja, P.) Ch. 11 (Springer, 2018).
Cited by
Sorted by citations
Items 101–101 of 101
Recent advances in systemic lupus erythematosus and microbiota: from bench to bedside
Zhan, Y., Liu, Q., Zhang, B., Huang, X., & Lu, Q. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0957-7 · Cited by 3
Metadata
- Authors
- Mocanu, V., Zhang, Z., Deehan, E. C., Kao, D. H., Hotte, N., Karmali, S., Birch, D. W., Samarasinghe, K. K., Walter, J., & Madsen, K. L.
- Affiliations
- University of Alberta (CA)
- University College Cork (IE)
- Corresponding author
- Madsen, Karen L.
- ORCID
- Venue
- Nature Medicine
- Published
- 2021-07
- Volume
- 27
- Issue
- 7
- Pages
- 1272-1279
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3182371690
- Cited by
- 328
- References
- 55
- Citations by year
- 2026: 51 · 2025: 77 · 2024: 67 · 2023: 56 · 2022: 65 · 2021: 12
- FWCI
- 15.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Gouvernement du Canada | Canadian Institutes of Health Research
- University of Alberta Clinical Investigator Program
- Canadian Institutes for Health Research.
- The W. Garfield Weston Foundation.
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- fecal microbiota transplantation, dietary fiber supplementation, morbid obesity, metabolic syndrome, insulin sensitivity, cardiometabolic outcomes, gut microbiota
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Proof of Concept Study, Dietary Fiber, Double-Blind Method, Female, Fermentation, Humans, Insulin Resistance, Male, Middle Aged, Obesity, Morbid, Dietary Supplements, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review